A federal court last year put the kibosh on a deal whereby Allergan transferred to the tribe the Restasis patents, which the tribe then licensed back to Allergan, asserting tribal sovereign immunity to have generic companies' challenge to the patents dismissed.
A pharmaceutical company making generic drugs that include its proprietary extended-release drug delivery technology is hoping to close a $6.5 million round by the end of the month. Ezra Innovations uses a unique drug design licensed from the University of Arkansas to improve the consistency with which a drug is released from pills over time. […]
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.